RecruitingPhase 3NCT05400317
A Study to Evaluate the Efficacy and Safety of AD-218
A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia
Sponsor
Addpharma Inc.
Enrollment
520 participants
Start Date
Jul 27, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218
Eligibility
Min Age: 19 Years
Inclusion Criteria2
- A man or woman over 19 years old.
- Sign on ICF prior to study participation
Exclusion Criteria2
- History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
- Other exclusions applied
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAD-218
PO, Once daily(QD), 12weeks
DRUGAD-218A
PO, Once daily(QD), 12weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05400317
Related Trials
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT06686615163 locations
A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
NCT063149191 location
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
NCT069327051 location